Oncolinx's Biz Plan Competition Round

Oncolinx raised a round of funding on October 28, 2016. Investors include 43North.

Oncolinx is developing antibody-drug conjugates, which carry an Azonafide cytotoxin attached to an antibody specifically to tumor cells and not healthy cells, thereby avoiding many of the side effects…

Articles about Oncolinx's Biz Plan Competition Round: